Phenotypeca Ltd is a synthetic biology company combining yeast genomics technology with manufacturing expertise from the biopharmaceutical industry.  Founded in 2018, with head office at BioCity Nottingham, Phenotypeca’s R&D operations are based in the University of Nottingham’s Synthetic Biology Research Centre in the Biodiscovery Institute.

We use advance breeding of genetically diverse baker’s yeast to produce up to a billion novel strains for high-throughput screening.  From these we select production strains with optimal phenotypes for future biomanufacturing processes.  We are currently working in three research areas:

1. To optimise production processes to reduce the cost of vaccine production.

2. To develop yeast strains for the manufacture of diagnostic proteins, such as SARS-CoV-2 antigens, for immunological testing.

3. Developing next-generation baker’s yeast production strains for biopharmaceutical manufacturing.